A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 50,05 (+16,88%). A mediana é € 50,50 (+17,94%).

Comprar
  5
Manter
  1
Vender
  0

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • HeartFlow: plaque analysis becomes main growth driver

    HeartFlow presented plaque analysis as its most important near-term growth driver at the Wells Fargo conference and projects about $30 million in revenue for 2026 versus $1.5 million in 2025. In Q2 2026 revenue rose 48% to over $64 million with a gross margin of roughly 82%. The company has about $250 million in cash, aims for profitability by mid-2028, and sees an expanded addressable market from $5 billion to $11 billion through expansion into asymptomatic high-risk patients; a broader product rollout including PCI Navigator is planned for 2027. » Mais em de.investing.com


  • Heartflow climbs to new record high of $51.26

    Heartflow stock reached an all-time high of $51.26 after strong gains in recent months (about +110% in 6 months, +73% year-to-date). In Q2 2026 the company reported adjusted earnings of -$0.07 per share and revenue up 48% to $64.1 million, with both metrics beating estimates. In response, Stifel raised its price target to $45.00 and reiterated a "Buy" rating, while some valuations consider the stock overvalued relative to fair value. » Mais em de.investing.com


  • Heartflow hits record high of $48.70 after strong Q2 results

    Heartflow shares rose to a record high of $48.70, about 1% below the 52-week high; the stock is up 86% over the past six months. In Q2 2026 the company beat expectations with adjusted EPS of -$0.07 (estimate -$0.19) and revenue rising 48% to $64.1 million. Stifel raised its price target to $45.00 and affirmed its "Buy" rating, while InvestingPro notes the stock may be overvalued at current levels. » Mais em de.investing.com


  • HeartFlow beats Q2 expectations, raises full-year guidance and stock jumps after hours

    HeartFlow reported an adjusted loss per share of $0.07 for Q2 2026, beating consensus by $0.12. Revenue rose 48% to $64.1 million and gross margin climbed to 83.3%, driven by strong plaque business and AI-powered automation. The company raised its full-year guidance to $246–250 million in revenue and a non-GAAP gross margin of about 82%; the stock rose roughly 16–17% after hours. While HeartFlow remains unprofitable, it expects to be cash-flow positive by mid-2028 and is showing accelerated revenue and margin growth. » Mais em de.investing.com


  • HeartFlow beats Q1 forecasts, raises full-year outlook — shares slightly weaker

    HeartFlow reported Q1 2026 EPS of -$0.16, beating the expected -$0.22; revenue rose 41% to $52.6 million. Non-GAAP gross margin improved to 80.5% and the non-GAAP net loss narrowed to $13.3 million. The company received positive feedback on new products such as the PCI Navigator and raised its 2026 revenue guidance to $228–232 million. Despite the results, the stock slipped 0.61% in after-hours trading. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, HeartFlow registou receitas de € 64,32 mi e um ganho líquido de -€ 10,16 mi
(EUR) setembro de 2026
YoY
Receitas 64,32 mi 63,12%
Ganho bruto 53,78 mi 78,21%
Ganho líquido -10,16 mi 76,56%
EBITDA -10,13 mi 73,74%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 3,73 bi
Número de ações
87,89 mi
Máximo/mínimo de 52 semanas
€ 55,20 - € 18,32
Dividendos Não
Beta
2,02
PER (PE Ratio)
-50,70
PEG (PEG Ratio)
-0,81
P/VC (PB Ratio)
14,40
P/V (PS Ratio)
17,18

Perfil da empresa

A HeartFlow, Inc., uma empresa de tecnologia médica, disponibiliza soluções não invasivas para o diagnóstico e gestão de doenças das artérias coronárias em todo o mundo. A sua HeartFlow Platform utiliza IA e dinâmica de fluidos computacional para criar um modelo 3D personalizado do coração de um doente a partir de uma única angiografia coronária por tomografia computorizada, um tipo especializado de exame que fornece imagens detalhadas das artérias do coração. A plataforma da empresa fornece informações sobre o fluxo sanguíneo, a estenose e o volume e composição da placa, superando as limitações dos testes de imagiologia não invasivos tradicionais. A empresa foi fundada em 2007 e tem a sua sede em Mountain View, Califórnia.

Nome
HeartFlow
CEO
John Farquhar
Site
Entrada em bolsa
07/08/2025
Colaboradores 843
🍪

Parqet  utiliza cookies. Saber mais